$SPRY

4 stories mentioning SPRY

Every FINWIRES story that references SPRY, newest first.

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) shedding 1%.The iShares Biotechnology ETF (IBB) dropped 2.4%.In corporate news, Thermo Fisher Scientific (TMO) could benefit from improving end-market conditions and recovering biotech funding, though "structural risks" may limit the company's ability to achieve its long-term organic growth aspiration, RBC Capital Markets said in a note. RBC resumed coverage of Thermo Fisher with a sector perform rating and a $490 price target. Thermo Fisher shares were down 2.3%.Aardvark Therapeutics (AARD) shares fell 32% after the firm said the US Food and Drug Administration placed a full clinical hold on its investigational new drug application for ARD-101. Morgan Stanley downgraded the stock to underweight from equalweight, and BTIG downgraded to neutral from buy.DexCom (DXCM) said Friday it has set new long-term financial goals, including organic revenue growth of more than 10% a year through 2030. Its shares climbed past 6%.ARS Pharmaceuticals (SPRY) shares fell 7% after it posted a wider Q1 loss.

$AARD$DXCM$SPRY$TMO

Sectors31d ago

Sector Update: Healthcare Stocks Softer Friday Afternoon

Healthcare stocks declined Friday afternoon, with the NYSE Healthcare Index falling 0.9% and the State Street Healthcare Select Sector SPDR ETF (XLV) shedding 0.8%.The iShares Biotechnology ETF (IBB) dropped 2.5%.In corporate news, Aardvark Therapeutics (AARD) shares fell 31% after the firm said the US Food and Drug Administration placed a full clinical hold on its investigational new drug application for ARD-101. Morgan Stanley downgraded the stock to underweight from equalweight, and BTIG to neutral from buy.DexCom (DXCM) said Friday it has set new long-term financial goals, including organic revenue growth of more than 10% a year through 2030. Its shares climbed past 6%.ARS Pharmaceuticals (SPRY) shares fell nearly 5% after it posted a wider Q1 net loss.Alumis (ALMS) stock was down more than 5% after it reported that its Q1 revenue dropped to $1.7 million from $17.4 million a year earlier.

$AARD$ALMS$DXCM$SPRY

Sectors31d ago

Sector Update: Healthcare Stocks Mixed Premarket Friday

Healthcare stocks were mixed pre-bell Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) slightly advancing and iShares Biotechnology ETF (IBB) down 0.2%.Alumis (ALMS) stock was down more than 10% after the company reported that its Q1 revenue slumped to $1.7 million from $17.4 million a year earlier.ARS Pharmaceuticals (SPRY) shares were down more than 20% after the company posted a wider Q1 net loss.Aardvark Therapeutics (AARD) stock was down more than 33% after the company said the US Food and Drug Administration placed a full clinical hold on its investigational new drug application for ARD-101 to treat hyperphagia associated with Prader-Willi Syndrome.

$AARD$ALMS$IBB$SPRY$XLV

Sectors61d ago

Sector Update: Health Care Stocks Rise Pre-Bell Wednesday

Health care stocks were rising pre-bell Wednesday with the State Street Health Care Select Sector SPDR ETF (XLV) 0.1% higher and the iShares Biotechnology ETF (IBB) up 0.4%.Mesoblast (MESO) shares were up more than 4% after the company said it acquired an exclusive worldwide license to a chimeric antigen receptor technology platform for augmentation of therapeutic mesenchymal lineage stromal cell products.ARS Pharmaceuticals (SPRY) stock was up more than 1% after the company said Health Canada has approved its neffy 2mg nasal spray for the emergency treatment of anaphylaxis.Immutep (IMMP) shares rose by more than 178% after the company said the US Food and Drug Administration has granted orphan drug designation to eftilagimod alfa for the treatment of soft tissue sarcoma, a rare cancer.

$IBB$IMMP$MESO$SPRY$XLV